ADI has expertise in the full range of drug
development from pre-IND through NDA
submissions and post registration trials (phase I
through IV).  ADI can assist clients in assessing
the specific development needs of a product,
including regulatory strategies or strategic
commercialization.  Whether it is limited phase 1
strategies, proof-of-concept, or a full clinical
development plan, ADI can assist in planning
and managing the full development program. ADI
has global expertise in the development of
products, including the US, Europe, and Japan.
Consulting Services in
Clinical Drug Development
Strategic planning
Clinical Development Plans
Product Development Plans
In-license evaluation
Thought leader relations
Phase I through IV study coordination
Protocol writing and CRF design
Investigator search and screening
CRO selection and management
Clinical and scientific report writing
While ADI can assist across multiple
therapeutic areas, some key strengths include:
Anti-infectives drug development
Pediatric drug development
Japan & Asian strategies
Services include: